Clinical Trial Design for Target-Based Therapy

Clinical Trial Design for Target-Based Therapy Elizabeth Fox, Gregory A. Curt, Frank M. Balis Oncologist 2002; 7: 401-409 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in clinical pharmacology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Differentiate between cytotoxic and molecularly-targeted drug development in terms of drug discovery, mechanism of action, pharmacological effect, and specificity. Define the primary objectives of phase I, II, and III clinical trials of cytotoxic and molecularly-targeted anticancer agents. Compare the end points used in clinical trials for cytotoxic agents to the proposed end points for target-based (cytostatic) agents. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Oct. 25, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Oct. 25, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.